RENB renovarobio.com Final Profit

Corporate emblem and logo of renovarobio.com (RENB)

The success of Renovaro Inc. (RENB) depends on the integration of AI into oncology diagnostics and the commercialization of its technologies. The company's net economic effect confirms this trend, where the current value equals -0.07. The biotech firm creates personalized vaccines for healthcare by utilizing neural networks in gene therapy. Currently, the brand is strengthening confidence in its early cancer detection platform, sparking modest interest from institutional investors.

RENB (Enochian BioSciences) Net Profit history from 02/21/2024 to 10/01/2025

Analytical breakdowns and data insights for company renovarobio.com (RENB)

- stock value and consensus price forecast:
Market Price Renovaro|RENB - Price Target Chart
- market capitalization data:
Market Value RENB|RENB - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Renovaro|RENB - Book Capitalization|Market Cap to Net Assets Ratio renovarobio.com|RENB - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Renovaro Inc.|RENB - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Renovaro|RENB - Company Aggregate Debts|Debts to Book Value RENB|RENB - Company Long-Term Debt|Company Short-Term Loans and Borrowings Renovaro|Immediate Liquidity renovarobio.com
- net income and valuation multiples indicators:
RENB - Company Net Income
Fundamental valuation:RENB Enochian BioSciences
Manufactured product of Renovaro Biosciences

This indicator serves as the basis for assessing the financial stability of Renovaro Inc. (RENB), reflecting daily net profit minus all operating expenses. By analyzing the company's actual profit, recorded at -0.07, an investor can see the impact of peak R&D expenditures on the synergy between AI diagnostics and cell therapy, which is critically important during the preparation for breakthrough technological releases.

Main competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Company Net Income Accuray Incorporated (ARAY)|SLS (sellaslifesciences.com) - Final Profit|Net Profit ACTU (Actuate Therapeutics)|Citius Oncology Inc. (CTOR) - Company Net Income|HURA - Company Net Income|TARA (Protara Tx) - Company Profit|Fate Therapeutics, Inc. (FATE) - Company Net Income|Company Net Income Aadi Bioscience (WHWK)|Net Income TCRX|Company Net Income CSBR|Net Profit XBIT|Net Profit cel-sci.com (CVM)|Company Net Income OS Therapies Incorporated OSTX|Final Profit RADX|ARTV - Company Net Income|Company Net Income Adlai Nortye Ltd.|VERU (Veru Pharma) - Net Income|Tempest Therapeutics Corp - Final Profit|XLO (Xilio Therapeutics Inc) - Net Profit|Mural Bio (MURA) - Net Financial Result|Company Net Income Kairos Pharma Ltd (KAPA)|onkuretherapeutics.com - Company Profit|Net Profit GDTC (CytoMed Therapeutics Limited)|CRIS - Net Income|APLM: Net Income|Net Financial Result tharimmune.com THAR|advanbiomed.com (ADVB) - Company Net Income|Genprex Inc. - Final Profit|CLDI (Calidi Biotherapeutics Inc.) - Net Profit|Company Net Income Sunshine Biopharma Inc. SBFM|Company Net Income Xenetic Biosciences (XBIO)|salariuspharma.com - Company Profit|Net Profit PPBT (Purple Biotech Ltd.)|American Oncology Network Inc - Company Net Income|BeOne Medicines - Net Profit|Checkpoint Therapeutics Inc (CKPT) - Net Income|ELEV: Net Profit|iCAD (ICAD) - Net Profit|Company Net Income Ikena Oncology Inc.|Company Profit NTBL (Notable Labs Ltd)|Net Profit VIRX|Net Income MorphoSys Corporation MOR|Net Profit NAYA (NAYA Biosciences)|ascentage.com (AAPGV) - Company Net Income